Dan Vaagen

Dan Vaagen is a seasoned finance and operations leader in biotechnology, currently serving as the Head of US Rare Disease Business Analytics & Forecasting at UCB. With a background in strategic planning and analytics, Dan has demonstrated success in driving performance and operational excellence in high-stakes environments. Dan previously held roles such as Director of Financial Planning & Analysis at both UCB and Shionogi Inc., and has experience as a Management Consultant and Staff Accountant. Dan began their career as an Infantryman in the US Army from 1992 to 1996. Dan is currently pursuing an MBA in Business Administration at Kennesaw State University and holds a BBA in Corporate Finance & Investments from East Tennessee State University.